Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer

Expert Opinion on Biological Therapy

Volumn 14, Issue 7, 2014, Pages 947-954

  Marcus, Assaf ^a   Eshhar, Zelig ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Adoptive cell transfer; Allogeneic; Cancer; CD19; Chimeric antigen receptors; Egress; FTY720; Graft versus host disease; Graft versus tumor; Her2 neuregulin; Host versus graft; T body; T cell receptor disruption; Tumor

Indexed keywords

ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG; ANTIGEN; CD19 ANTIGEN; HYBRID PROTEIN; TUMOR ANTIGEN;

ADOPTIVE CELL THERAPY; ALLOGENEIC ADOPTIVE CELL TRANSFER; ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELL; ALLOIMMUNITY; CANCER THERAPY; CELL THERAPY; CELL TRANSFER; DONOR LYMPHOCYTE INFUSION; GAMMA DELTA T LYMPHOCYTE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NONHUMAN; REVIEW; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; B LYMPHOCYTE; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; LEUKEMIA, B-CELL; METABOLISM; NEOPLASMS; PROCEDURES; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANTIGENS; ANTIGENS, CD19; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LEUKEMIA, B-CELL; NEOPLASMS; RECEPTORS, ANTIGEN; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84902140053     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.900540     Document Type: Review

References (35)

1. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8(4):299-308
2. Leen AM, Tripic T, Rooney CM. Challenges of T cell therapies for virusassociated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther 2010;10(3):337-51
3. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumorinfiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319(25):1676-80
4. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298(5594):850-4
5. Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001;83:117-58
6. Crespo J, Sun H, Welling TH, et al. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol 2013;25(2):214-21
7. Barrett DM, Singh N, Porter DL, et al. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014;65:333-47
8. Cheadle EJ, Gornall H, Baldan V, et al. CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev 2014;257(1):91-106
9. Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol 2008(181):329-42
10. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21(2): 215-23
11. Friedmann-Morvinski D, Bendavid A, Waks T, et al. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 2005;105(8):3087-93
12. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5(177):177ra38
13. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118(18):4817-28
14. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368(16):1509-18
15. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116(20):4099-102
16. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365(8):725-33
17. Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013;122(25):4129-39
18. Porter DL, Kalos M, Frey NV, et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. Proceedings of the 55th annual meeting of the American Society of Hematology; 2013
19. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18(4): 843-51
20. Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013;31(1):71-5
21. Lanitis E, Poussin M, Klattenhoff AW, et al. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused anti-tumor activity with reduced potential for toxicity. Cancer Immunol Res 2013;1(1):43-53
22. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 2013;5(215):215ra172
23. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007;25:139-70
24. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75(3):555-62
25. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979;300(19):1068-73
26. Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004;103(3):790-5
27. Dazzi F, Goldman JM. Adoptive immunotherapy following allogeneic bone marrow transplantation. Annu Rev Med 1998;49:329-40
28. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15(2):433-44
29. Davies JK, Singh H, Huls H, et al. Combining CD19 redirection and alloanergization to generate tumorspecific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res 2010;70(10):3915-24
30. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in graft-versus-host disease (GVHD). Blood 2007;110(9):3480-8
31. Takada K, Jameson SC. Self-class I MHC molecules support survival of naive CD8 T cells, but depress their functional sensitivity through regulation of CD8 expression levels. J Exp Med 2009;206(10):2253-69
32. Whitmore WF Jr. Natural history and staging of prostate cancer. Urol Clin North Am 1984;11(2):205-20
33. Bondanza A, Valtolina V, Magnani Z, et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 2006;107(5):1828-36
34. Straathof KC, Pule MA, Yotnda P, et al. An inducible caspase 9 safety switch for Tcell therapy. Blood 2005;105(11):4247-54
35. Wang H, Yang H, Shivalila CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013;153(4):910-18